17 January 2025 - Shanghai Junshi Biosciences announced that toripalimab, the anti-PD-1 monoclonal antibody self-developed by the company, has obtained the marketing authorisation issued by the TGA of the Australian Government Department of Health and Aged Care. 

The new chemical entity application for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma and toripalimab, as a single agent, for the treatment of adults with recurrent unresectable or metastatic nasopharyngeal carcinoma with disease progression on or after a platinum-containing chemotherapy has been approved by TGA.

Read Junshi Biosciences press release